Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of MRG002 versus investigator's choice chemotherapy in HER2-positive advanced or metastatic urothelial carcinoma after platinum and PD-1/PD-L1 therapy
CTR20230243Phase 3Active
- Sponsor
- Hangzhou Miracogen
- Start
- Apr 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of MRG002 in transitional cell carcinoma (TCC), sponsored by Hangzhou Miracogen. Started Apr 2023; status: active.
02
Drugs
MRG002
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20230243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230243.